Cellectis S.A. Banner Image

Cellectis S.A.

  • Ticker CLLS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cellectis S.A. Logo Image
  • 201-500 Employees
  • Based in Paris, France
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR Tcells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALENĀ®, its geneMore editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
4.8 / 5.0 (125)

Cellectis S.A. reports have an aggregate usefulness score of 4.8 based on 125 reviews.

Cellectis S.A.

Most Recent Annual Report

Cellectis S.A.
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Cellectis S.A. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!